https://m2.mtmt.hu/ hun 2026-10-25 02:09 JournalArticle 37325625 VALIDATED true 0 false 2026-10-19T12:13:50.141+0000 2026-10-13T15:57:02.010+0000 2026-06-08T08:51:48.760+0000 true 10066331 Vida Zsuzsa Ágnes /api/admin/10066331 Admin Vida Zsuzsa Ágnes (DE/ÁOK/ElettI Admin 5, admin) true 2026-10-19T12:09:47.994+0000 2026-10-13T15:57:01.958+0000 true 521 Szuper Admin /api/admin/521 Admin Szuper Admin (admin) true true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 1134514 Survey paper true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/1134514 Összefoglaló cikk SubType Összefoglaló cikk (Folyóiratcikk) 102 true 1134514 true 1 /api/category/1 Category Tudományos true 1 Kovács, Zsigmond Máté true true /api/journal/10024432 REVIEWED PHARMACEUTICALS 1424-8247 true false 10024432 false 10024432 true 1424-8247 Journal FOREIGN 19 6 882 882 19 2026 Our review focuses on methanesulfonamide-containing compounds, a well-characterized class of high-affinity blockers of the hERG potassium channel, which plays a critical role in cardiac repolarization by mediating the cardiac IKr. These compounds, which include notable class III antiarrhythmic drugs such as dofetilide and d-sotalol, block the hERG channel in its open state by binding within the inner vestibule. This interaction is particularly strong with some residues and the compounds form hydrogen bonds with others. This binding results in high-affinity inhibition with slow dissociation kinetics, frequently leading to drug trapping and prolonged action potential duration (APD). This can predispose patients to arrhythmias, including Torsades de Pointes. Beyond cardiac drugs, there are several non-cardiac methanesulfonamide drugs that also block the hERG channel. This causes pro-arrhythmic side effects despite their primary indications. The clinical significance of these effects, especially in patients with impaired drug elimination, is that accumulation increases the risk of arrhythmia. The objective of forthcoming research endeavors is to mitigate hERG affinity, with the aim of reducing pro-arrhythmic risks while maintaining therapeutic efficacy. This means structural modifications that seek to remove or modify the methanesulfonamide group. Machine learning also emerged as promising tool for exploring drug–protein interactions. It is evident that the methanesulfonamide moiety plays a pivotal role in the structural basis of hERG blockade. However, it should be noted that this moiety does not necessarily represent a universal pharmacophore. This observation underscores the necessity for a nuanced approach in drug development, aimed at achieving a balance between efficacy and safety. Funding 2067751 /api/funding/2067751 Adaptív és maladaptív jelátviteli mechanizmusok vizsgálata humán és emlôs szívben és agyszövetben(K 138090) Támogató: NKFIH false true Funding 2067752 /api/funding/2067752 A TRPM4 ioncsatorna elektrofiziológiai szerepének vizsgálata emlősszíven(K 142764) Támogató: NKFIH false true Funding 2067753 /api/funding/2067753 Mechanikai terhelés hatása a szív elektromechanikai kapcsolatára(K 147301) Támogató: NKFIH false true Funding 2067754 /api/funding/2067754 (K139293) false true Funding 2067755 /api/funding/2067755 A direkt miozin-inhibitor aficamten elektrofiziológiai hatásai kutya kamrai szívizomsejteken(EKÖP-25-3-II-DE-105) Támogató: EKÖP false true true 2026 true true true false true false GOLD 2026-10-19 false http://www.mdpi.com/journal/pharmaceuticals 1 0 1 0 1 1 1 0 1 1 1 0 0 0 1 0 1 0 1 0 0 7 7 Folyóiratcikk Journal Article 24 1 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2026 0 1 0 1 0 Q1 false false false false 2026-09-06T08:54:11.311+0000 Klinikai Laboratóriumi Kutató Tanszék (DE / ÁOK / LMI); Sport- és Űrélettani Nem Önálló Tanszék (DE / ÁOK / ElettI); Élettani Intézet (DE / ÁOK) 8 20 3 8 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 139397766 /api/authorship/139397766 Kovács, Zsigmond Máté [Kovács, Zsigmond Máté (élettan), szerző] Élettani Intézet (DE / ÁOK) 1 0.125 true false false Author 10079012 /api/author/10079012 Kovács Zsigmond Máté (élettan) Kovács Zsigmond Máté true true Kovács Zsigmond Máté true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 139397767 /api/authorship/139397767 Óvári, József [Óvári, József (orvostudomány), szerző] Élettani Intézet (DE / ÁOK) 2 0.125 false false false Author 10084683 /api/author/10084683 Óvári József (orvostudomány) Óvári József true true Óvári József true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 139397768 /api/authorship/139397768 Magyar, János [Magyar, János (Élettan, kórélettan), szerző] Élettani Intézet (DE / ÁOK); Sport- és Űrélettani Nem Önálló Tanszék (DE / ÁOK / ElettI) 3 0.125 false false false Author 10001709 /api/author/10001709 Magyar János (Élettan, kórélettan) Magyar János true 10001709 true Magyar János true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 139397769 /api/authorship/139397769 Bányász, Tamás [Bányász, Tamás (Élettan, kórélettan), szerző] Élettani Intézet (DE / ÁOK) 4 0.125 false false false Author 10001771 /api/author/10001771 Bányász Tamás (Élettan, kórélettan) Bányász Tamás true 10001771 true Bányász Tamás true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 139397770 /api/authorship/139397770 Nánási, Péter P. [Nánási, Péter Pál (Élettan és kóréle...), szerző] Élettani Intézet (DE / ÁOK) 5 0.125 false false false Author 10005920 /api/author/10005920 Nánási Péter Pál (Élettan és kórélettan) Nánási Péter Pál true 10005920 true Nánási Péter P. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 139397771 /api/authorship/139397771 Horváth, Balázs [Horváth, Balázs (Élettan), szerző] Élettani Intézet (DE / ÁOK) 6 0.125 false false false Author 10036941 /api/author/10036941 Horváth Balázs (Élettan) Horváth Balázs true 10036941 true Horváth Balázs true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 139397772 /api/authorship/139397772 Balogh, Gábor [Balogh, Gábor (számítási kémia, ...), szerző] Klinikai Laboratóriumi Kutató Tanszék (DE / ÁOK / LMI) 7 0.125 false false false Author 10054274 /api/author/10054274 Balogh Gábor (számítási kémia, szerkezeti biológia) Balogh Gábor true 10054274 true Balogh Gábor true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 139397773 /api/authorship/139397773 Szentandrássy, Norbert ✉ [Szentandrássy, Norbert (élettan), szerző] Élettani Intézet (DE / ÁOK) 8 0.125 false true true Author 10019012 /api/author/10019012 Szentandrássy Norbert (élettan) Szentandrássy Norbert true 10019012 true Szentandrássy Norbert true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 32475615 /api/publicationidentifier/32475615 DOI: 10.3390/ph19060882 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.3390/ph19060882 https://doi.org/10.3390/ph19060882 false true PublicationIdentifier 32589879 /api/publicationidentifier/32589879 WoS: 001803776300001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001803776300001 https://www.webofscience.com/wos/woscc/full-record/001803776300001 false true PublicationIdentifier 32598224 /api/publicationidentifier/32598224 Scopus: 105042882284 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 105042882284 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105042882284 true true PublicationIdentifier 32589880 /api/publicationidentifier/32589880 PubMed: 42356500 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true 42356500 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=42356500&dopt=Abstract false true PublicationIdentifier 32475616 /api/publicationidentifier/32475616 Egyéb URL: https://www.mdpi.com/1424-8247/19/6/882 PlainSource 40 /api/publicationsource/40 Egyéb URL PublicationSourceType 10006 /api/publicationsourcetype/10006 Link true true true Egyéb URL Other URL @@@ true true 40 true https://www.mdpi.com/1424-8247/19/6/882 https://www.mdpi.com/1424-8247/19/6/882 false true Classification 12125 /api/classification/12125 Általános orvostudomány true true Classification 12184 /api/classification/12184 Farmakológia és gyógyszerészet true true Classification 12208 /api/classification/12208 Fiziológia (benne citológia) true true Classification 12124 /api/classification/12124 Orvos- és egészségtudomány true true Keyword 1414675 /api/keyword/1414675 methanesulfonamide true 1414675 true Keyword 1957867 /api/keyword/1957867 hERG channel true true Keyword 2147696 /api/keyword/2147696 class III antiarrhythmics true true Keyword 2693077 /api/keyword/2693077 Action potentials (APs) true true Keyword 2991385 /api/keyword/2991385 rapid component of the delayed rectifier potassium current (IKr) true true SjrRating 11715900 /api/sjrrating/11715900 sjr:Q1 (2026) Scopus - Drug Discovery PHARMACEUTICALS 1424-8247 33 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 3002 /api/classificationexternal/3002 Scopus - Drug Discovery true 3002 true Q1 FROM_LAST_YEAR true true Reference 75862483 /api/reference/75862483 1. Hales, C.M., Servais, J., Martin, C.B., and Kohen, D. (2019). Prescription Drug Use Among Adults Aged 40–79 in the United States and Canada. NCHS Data Briefs, 347. 1 false true Reference 75862484 /api/reference/75862484 2. Ahmad 2024: Mortality in the United States—Provisional Data, 2023., MMWR. Morb. Mortal. Wkly. Rep., 73, p. 677, DOI: 10.15585/mmwr.mm7331a1 2 10.15585/mmwr.mm7331a1 false true Reference 75862485 /api/reference/75862485 3. Huggins 2012: Rational Approaches to Improving Selectivity in Drug Design., J. Med. Chem., 55, p. 1424, DOI: 10.1021/jm2010332 3 10.1021/jm2010332 false true Reference 75862486 /api/reference/75862486 4. Duarte 2007: Privileged Structures: A Useful Concept for the Rational Design of New Lead Drug Candidates., Mini-Rev. Med. Chem., 7, p. 1108, DOI: 10.2174/138955707782331722 4 10.2174/138955707782331722 false true Reference 75862487 /api/reference/75862487 5. Chen 2016: Scaffold Repurposing of Old Drugs Towards New Cancer Drug Discovery., Curr. Top. Med. Chem., 16, p. 2107, DOI: 10.2174/1568026616666160216155556 5 10.2174/1568026616666160216155556 false true Reference 75862488 /api/reference/75862488 6. Liabeuf, S., Berdougo-Tritz, J., Augey, L., Mbarek, A., Jadoul, M., Deray, G., and Massy, Z.A. (2025). Drug Exposure in Chronic Kidney Disease: It Is Not Just About the Glomerular Filtration Rate. Fundam. Clin. Pharmacol., 39., DOI: 10.1111/fcp.70037 6 10.1111/fcp.70037 false true Reference 75862489 /api/reference/75862489 7. Hanumegowda, U.M., and Davis, C. (2022). The Role of Drug Metabolism in Toxicity. Drug Metabolism Handbook: Concepts and Applications in Cancer Research, Wiley., DOI: 10.1002/9781119851042.ch19 7 10.1002/9781119851042.ch19 false true Reference 75862490 /api/reference/75862490 8. McLean 1991: Clinical Pharmacokinetics in Patients with Liver Disease., Clin. Pharmacokinet., 21, p. 42, DOI: 10.2165/00003088-199121010-00004 8 10.2165/00003088-199121010-00004 false true Reference 75862491 /api/reference/75862491 9. Domagk 1935: Ein Beitrag Zur Chemotherapie Der Bakteriellen Infektionen., Dtsch. Med. Wochenschr., 61, p. 250, DOI: 10.1055/s-0028-1129486 9 10.1055/s-0028-1129486 false true Reference 75862492 /api/reference/75862492 10. Dias 2020: From Antibacterial to Antitumour Agents: A Brief Review on The Chemical and Medicinal Aspects of Sulfonamides., Mini-Rev. Med. Chem., 20, p. 2052, DOI: 10.2174/1389557520666200905125738 10 10.2174/1389557520666200905125738 false true Reference 75862493 /api/reference/75862493 11. Talamas 2014: Discovery of N-[4-[6-Tert-Butyl-5-Methoxy-8-(6-Methoxy-2-Oxo-1 H -Pyridin-3-Yl)-3-Quinolyl]Phenyl]Methanesulfonamide (RG7109), a Potent Inhibitor of the Hepatitis C Virus NS5B Polymerase., J. Med. Chem., 57, p. 1914, DOI: 10.1021/jm401329s 11 10.1021/jm401329s false true Reference 75862494 /api/reference/75862494 12. Zeuzem 2014: Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin., N. Engl. J. Med., 370, p. 1604, DOI: 10.1056/NEJMoa1401561 12 10.1056/NEJMoa1401561 false true Reference 75862495 /api/reference/75862495 13. Droc 2022: Safety and Efficacy of Direct-Acting Antiviral Therapies for Chronic HCV Infection in Hemodialysis Patients., In Vivo, 36, p. 2918, DOI: 10.21873/invivo.13033 13 10.21873/invivo.13033 false true Reference 75862496 /api/reference/75862496 14. Wang 2019: Current and Emerging Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) for HIV-1 Treatment., Expert Opin. Drug Metab. Toxicol., 15, p. 813, DOI: 10.1080/17425255.2019.1673367 14 10.1080/17425255.2019.1673367 false true Reference 75862497 /api/reference/75862497 15. Hwang 2007: Chemoprotective Effect of Insulin-like Growth Factor I against Acetaminophen-Induced Cell Death in Chang Liver Cells via ERK1/2 Activation., Toxicology, 230, p. 76, DOI: 10.1016/j.tox.2006.11.001 15 10.1016/j.tox.2006.11.001 false true Reference 75862498 /api/reference/75862498 16. Paduch 2011: Nitric Oxide (NO) and Cyclooxygenase-2 (COX-2) Cross-Talk in Co-Cultures of Tumor Spheroids with Normal Cells., Cancer Microenviron., 4, p. 187, DOI: 10.1007/s12307-011-0063-x 16 10.1007/s12307-011-0063-x false true Reference 75862499 /api/reference/75862499 17. Mitcheson 2000: A Structural Basis for Drug-Induced Long QT Syndrome., Proc. Natl. Acad. Sci. USA, 97, p. 12329, DOI: 10.1073/pnas.210244497 17 10.1073/pnas.210244497 false true Reference 75862500 /api/reference/75862500 18. Kamiya 2006: Molecular Determinants of HERG Channel Block., Mol. Pharmacol., 69, p. 1709, DOI: 10.1124/mol.105.020990 18 10.1124/mol.105.020990 false true Reference 75862501 /api/reference/75862501 19. Kalyaanamoorthy 2018: Development of Safe Drugs: The HERG Challenge., Med. Res. Rev., 38, p. 525, DOI: 10.1002/med.21445 19 10.1002/med.21445 false true Reference 75862502 /api/reference/75862502 20. Durdagi 2012: Modeling of Open, Closed, and Open-Inactivated States of the HERG1 Channel: Structural Mechanisms of the State-Dependent Drug Binding., J. Chem. Inf. Model., 52, p. 2760, DOI: 10.1021/ci300353u 20 10.1021/ci300353u false true Reference 75862503 /api/reference/75862503 21. Chen 2011: A Critical Assessment of Combined Ligand- and Structure-Based Approaches to HERG Channel Blocker Modeling., J. Chem. Inf. Model., 51, p. 2948, DOI: 10.1021/ci200271d 21 10.1021/ci200271d false true Reference 75862504 /api/reference/75862504 22. Ekins 2002: Three-Dimensional Quantitative Structure-Activity Relationship for Inhibition of Human Ether-a-Go-Go-Related Gene Potassium Channel., J. Pharmacol. Exp. Ther., 301, p. 427, DOI: 10.1124/jpet.301.2.427 22 10.1124/jpet.301.2.427 false true Reference 75862505 /api/reference/75862505 23. Cavalli 2012: Computational Design and Discovery of “Minimally Structured” HERG Blockers., J. Med. Chem., 55, p. 4010, DOI: 10.1021/jm201194q 23 10.1021/jm201194q false true Reference 75862506 /api/reference/75862506 24. Aronov 2006: Common Pharmacophores for Uncharged Human Ether-a-Go-Go-Related Gene (HERG) Blockers., J. Med. Chem., 49, p. 6917, DOI: 10.1021/jm060500o 24 10.1021/jm060500o false true Reference 75862507 /api/reference/75862507 25. Kratz 2014: Experimentally Validated HERG Pharmacophore Models as Cardiotoxicity Prediction Tools., J. Chem. Inf. Model., 54, p. 2887, DOI: 10.1021/ci5001955 25 10.1021/ci5001955 false true Reference 75862508 /api/reference/75862508 26. Wang 2017: Cryo-EM Structure of the Open Human Ether-à-Go-Go-Related K+ Channel HERG., Cell, 169, p. 422, DOI: 10.1016/j.cell.2017.03.048 26 10.1016/j.cell.2017.03.048 false true Reference 75862509 /api/reference/75862509 27. Emigh Cortez, A.M., DeMarco, K.R., Furutani, K., Bekker, S., Sack, J.T., Wulff, H., Clancy, C.E., Vorobyov, I., and Yarov-Yarovoy, V. (2023). Structural Modeling of HERG Channel–Drug Interactions Using Rosetta. Front. Pharmacol., 14., DOI: 10.3389/fphar.2023.1244166 27 10.3389/fphar.2023.1244166 false true Reference 75862510 /api/reference/75862510 28. 2021: Computational Prediction of HERG Blockers Using Homology Modelling, Molecular Docking and QuaSAR Studies., Results Chem., 3, p. 100101, DOI: 10.1016/j.rechem.2021.100101 28 10.1016/j.rechem.2021.100101 false true Reference 75862511 /api/reference/75862511 29. Miyashita 2024: Improved Higher Resolution Cryo-EM Structures Reveal the Binding Modes of HERG Channel Inhibitors., Structure, 32, p. 1926, DOI: 10.1016/j.str.2024.08.021 29 10.1016/j.str.2024.08.021 false true Reference 75862512 /api/reference/75862512 30. Butler, A., Helliwell, M.V., Zhang, Y., Hancox, J.C., and Dempsey, C.E. (2020). An Update on the Structure of HERG. Front. Pharmacol., 10., DOI: 10.3389/fphar.2019.01572 30 10.3389/fphar.2019.01572 false true Reference 75862513 /api/reference/75862513 31. Stork 2007: State Dependent Dissociation of HERG Channel Inhibitors., Br. J. Pharmacol., 151, p. 1368, DOI: 10.1038/sj.bjp.0707356 31 10.1038/sj.bjp.0707356 false true Reference 75862514 /api/reference/75862514 32. Magyar 2007: Action Potential Clamp Fingerprints of K + Currents in Canine Cardiomyocytes: Their Role in Ventricular Repolarization., Acta Physiol., 190, p. 189, DOI: 10.1111/j.1748-1716.2007.01674.x 32 10.1111/j.1748-1716.2007.01674.x false true Reference 75862515 /api/reference/75862515 33. Szentandrassy 2011: Powerful Technique to Test Selectivity of Agents Acting on Cardiac Ion Channels: The Action Potential Voltage-Clamp., Curr. Med. Chem., 18, p. 3737, DOI: 10.2174/092986711796642418 33 10.2174/092986711796642418 false true Reference 75862516 /api/reference/75862516 34. Kiss 2021: Ion Current Profiles in Canine Ventricular Myocytes Obtained by the “Onion Peeling” Technique., J. Mol. Cell. Cardiol., 158, p. 153, DOI: 10.1016/j.yjmcc.2021.05.011 34 10.1016/j.yjmcc.2021.05.011 false true Reference 75862517 /api/reference/75862517 35. Tseng 2001: IKr: The HERG Channel., J. Mol. Cell. Cardiol., 33, p. 835, DOI: 10.1006/jmcc.2000.1317 35 10.1006/jmcc.2000.1317 false true Reference 75862518 /api/reference/75862518 36. Sanguinetti 1997: Molecular Physiology of Cardiac Delayed Rectifier K+ Channels., Heart Vessel., 12, p. 170 36 false true Reference 75862519 /api/reference/75862519 37. Sanguinetti 1995: A Mechanistic Link between an Inherited and an Acquired Cardiac Arrhytmia: HERG Encodes the IKr Potassium Channel., Cell, 81, p. 299, DOI: 10.1016/0092-8674(95)90340-2 37 10.1016/0092-8674(95)90340-2 false true Reference 75862520 /api/reference/75862520 38. Christophe 2022: Occurrence of Early Afterdepolarization under Healthy or Hypertrophic Cardiomyopathy Conditions in the Human Ventricular Endocardial Myocyte: In Silico Study Using 109 Torsadogenic or Non-Torsadogenic Compounds., Toxicol. Appl. Pharmacol., 438, p. 115914, DOI: 10.1016/j.taap.2022.115914 38 10.1016/j.taap.2022.115914 false true Reference 75862521 /api/reference/75862521 39. Curran 1995: A Molecular Basis for Cardiac Arrhythmia: HERG Mutations Cause Long QT Syndrome., Cell, 80, p. 795, DOI: 10.1016/0092-8674(95)90358-5 39 10.1016/0092-8674(95)90358-5 false true Reference 75862522 /api/reference/75862522 40. 1992: Classifying Antiarrhythmic Actions: By Facts or Speculation., J. Clin. Pharmacol., 32, p. 964, DOI: 10.1002/j.1552-4604.1992.tb03797.x 40 10.1002/j.1552-4604.1992.tb03797.x false true Reference 75862523 /api/reference/75862523 41. Mitcheson 2000: Trapping of a Methanesulfonanilide by Closure of the HERG Potassium Channel Activation Gate., J. Gen. Physiol., 115, p. 229, DOI: 10.1085/jgp.115.3.229 41 10.1085/jgp.115.3.229 false true Reference 75862524 /api/reference/75862524 42. Spector 1996: Class III Antiarrhythmic Drugs Block HERG, a Human Cardiac Delayed Rectifier K+ Channel Open-Channel Block by Methanesulfonanilides., Circ. Res., 78, p. 499, DOI: 10.1161/01.RES.78.3.499 42 10.1161/01.RES.78.3.499 false true Reference 75862525 /api/reference/75862525 43. Mitcheson 2000: Mechanism of Methanesulfonanilide Block of the HERG Potassium Channel., Jpn. J. Electrocardiol., 20, p. 67, DOI: 10.5105/jse.20.Suppl3_67 43 10.5105/jse.20.Suppl3_67 false true Reference 75862526 /api/reference/75862526 44. Wettwer 1991: Effects of the New Class Iii Antiarrhythmic Drug E-4031 on Myocardial Contractility and Electrophysiological Parameters., J. Cardiovasc. Pharmacol., 17, p. 480, DOI: 10.1097/00005344-199103000-00018 44 10.1097/00005344-199103000-00018 false true Reference 75862527 /api/reference/75862527 45. Okada 1996: Assessment of Reverse Use-Dependent Blocking Actions of Class III Antiarrhythmic Drugs by 24-hour Holter Electrocardiography., J. Am. Coll. Cardiol., 27, p. 84, DOI: 10.1016/0735-1097(95)00424-6 45 10.1016/0735-1097(95)00424-6 false true Reference 75862528 /api/reference/75862528 46. Nalos 2012: Comparison of the I Kr Blockers Moxifloxacin, Dofetilide and E-4031 in Five Screening Models of pro-Arrhythmia Reveals Lack of Specificity of Isolated Cardiomyocytes., Br. J. Pharmacol., 165, p. 467, DOI: 10.1111/j.1476-5381.2011.01558.x 46 10.1111/j.1476-5381.2011.01558.x false true Reference 75862529 /api/reference/75862529 47. Patterson 1984: Antiarrhythmic and Antifibrillatory Actions of the Beta Adrenergic Receptor Antagonist, Dl-Sotalol., J. Pharmacol. Exp. Ther., 230, p. 519, DOI: 10.1016/S0022-3565(25)21592-0 47 10.1016/S0022-3565(25)21592-0 false true Reference 75862530 /api/reference/75862530 48. Lessem 1986: Multicenter Trial of Sotalol for Suppression of Frequent, Complex Ventricular Arrhythmias: A Double-Blind, Randomized, Placebo-Controlled Evaluation of Two Doses., J. Am. Coll. Cardiol., 8, p. 752, DOI: 10.1016/S0735-1097(86)80414-4 48 10.1016/S0735-1097(86)80414-4 false true Reference 75862531 /api/reference/75862531 49. Lathrop 1990: Sotalol and Mexiletine: Combination of Rate-Dependent Electrophysiological Effects., J. Cardiovasc. Pharmacol., 16, p. 557, DOI: 10.1097/00005344-199010000-00006 49 10.1097/00005344-199010000-00006 false true Reference 75862532 /api/reference/75862532 50. Orvos 2019: Evaluation of Possible Proarrhythmic Potency: Comparison of the Effect of Dofetilide, Cisapride, Sotalol, Terfenadine, and Verapamil on HERG and Native i Kr Currents and on Cardiac Action Potential., Toxicol. Sci., 168, p. 365, DOI: 10.1093/toxsci/kfy299 50 10.1093/toxsci/kfy299 false true Reference 75862533 /api/reference/75862533 51. (2026, February 05). Tikosyn, (Dofetilide) Dosing, Indications, Interactions, Adverse Effects, and More. Available online: https://reference.medscape.com/drug/tikosyn-dofetilide-342298. 51 false true Reference 75862534 /api/reference/75862534 52. Gwilt 1991: UK-68,798: A Novel, Potent and Highly Selective Class III Antiarrhythmic Agent Which Blocks Potassium Channels in Cardiac Cells., J. Pharmacol. Exp. Ther., 256, p. 318, DOI: 10.1016/S0022-3565(25)23172-X 52 10.1016/S0022-3565(25)23172-X false true Reference 75862535 /api/reference/75862535 53. Kiehn 1996: Molecular Physiology and Pharmacology of HERG: Single-Channel Currents and Block by Dofetilide., Circulation, 94, p. 2572, DOI: 10.1161/01.CIR.94.10.2572 53 10.1161/01.CIR.94.10.2572 false true Reference 75862536 /api/reference/75862536 54. Weerapura 2002: Dofetilide Block Involves Interactions with Open and Inactivated States of HERG Channels., Pflug. Arch. Eur. J. Physiol., 443, p. 520, DOI: 10.1007/s004240100720 54 10.1007/s004240100720 false true Reference 75862537 /api/reference/75862537 55. Lee 2003: Differential Recovery of Action Potential Duration and HERG Currents from the Effects of Two Methanesulfonamide Class III Antiarrhythmic Agents, KCB-328 and Dofetilide., J. Cardiovasc. Pharmacol., 42, p. 648, DOI: 10.1097/00005344-200311000-00011 55 10.1097/00005344-200311000-00011 false true Reference 75862538 /api/reference/75862538 56. Plante 2012: Rosuvastatin Blocks HERG Current and Prolongs Cardiac Repolarization., J. Pharm. Sci., 101, p. 868, DOI: 10.1002/jps.22809 56 10.1002/jps.22809 false true Reference 75862539 /api/reference/75862539 57. Feng 2019: Intracellular Mechanism of Rosuvastatin-Induced Decrease in Mature HERG Protein Expression on Membrane., Mol. Pharm., 16, p. 1477, DOI: 10.1021/acs.molpharmaceut.8b01102 57 10.1021/acs.molpharmaceut.8b01102 false true Reference 75862540 /api/reference/75862540 58. Elson 1980: Acute Ventricular Fibrillation and Death during Infusion of 4’-(9-Acridinylamino)Methanesulfon-m-Anisidide (AMSA)., Cancer Treat. Rep., 64, p. 356 58 false true Reference 75862541 /api/reference/75862541 59. Schwartz 1984: QT Interval Prolongation and Cardiac Dysrhythmia in a Patient Receiving Amsacrine., Cancer Treat. Rep., 68, p. 1043 59 false true Reference 75862542 /api/reference/75862542 60. Shinar 1984: Acute Electrocardiographic Changes Induced by Amsacrine., Cancer Treat. Rep., 68, p. 1169 60 false true Reference 75862543 /api/reference/75862543 61. McLaughlin 1983: Ventricular Fibrillation Following AMSA. Uncomplicated Retreatment Following Correction of Hypokalemia., Cancer, 52, p. 557, DOI: 10.1002/1097-0142(19830801)52:3&lt;557::AID-CNCR2820520329&gt;3.0.CO;2-M 61 10.1002/1097-0142(19830801)52:3&lt;557::AID-CNCR2820520329&gt;3.0.CO;2-M false true Reference 75862544 /api/reference/75862544 62. Merkin 1985: The Effects of M-Amsa on Rat Isolated Heart., Clin. Exp. Pharmacol. Physiol., 12, p. 131, DOI: 10.1111/j.1440-1681.1985.tb02315.x 62 10.1111/j.1440-1681.1985.tb02315.x false true Reference 75862545 /api/reference/75862545 63. Thomas 2004: Inhibition of Cardiac HERG Currents by the DNA Topoisomerase II Inhibitor Amsacrine: Mode of Action., Br. J. Pharmacol., 142, p. 485, DOI: 10.1038/sj.bjp.0705795 63 10.1038/sj.bjp.0705795 false true Reference 75862546 /api/reference/75862546 64. Li 2017: Efficacy and Safety of Direct-Acting Antivirals-Based Antiviral Therapies for Hepatitis C Virus Patients with Stage 4–5 Chronic Kidney Disease: A Meta-Analysis., Liver Int., 37, p. 974, DOI: 10.1111/liv.13336 64 10.1111/liv.13336 false true Reference 75862547 /api/reference/75862547 65. Ucciferri 2018: Cardiac Toxicity Associated with HCV Direct Antiviral Agents., Mediterr. J. Hematol. Infect. Dis., 10, p. e2018069, DOI: 10.4084/mjhid.2018.069 65 10.4084/mjhid.2018.069 false true Reference 75862548 /api/reference/75862548 66. Suna 2019: Successful Treatment with Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients., Exp. Clin. Transplant., 17, p. 52, DOI: 10.6002/ect.2018.0095 66 10.6002/ect.2018.0095 false true Reference 75862549 /api/reference/75862549 67. Kovács, Z.M., Óvári, J., Dienes, C., Magyar, J., Bányász, T., Nánási, P.P., Horváth, B., Feher, A., Varga, Z., and Szentandrássy, N. (2023). ABT-333 (Dasabuvir) Increases Action Potential Duration and Provokes Early Afterdepolarizations in Canine Left Ventricular Cells via Inhibition of IKr. Pharmaceuticals, 16., DOI: 10.3390/ph16040488 67 10.3390/ph16040488 false true Reference 75862550 /api/reference/75862550 68. Dienes 2025: Delavirdine Modifies Action Potential Configuration via Inhibition of IKr and Ito in Canine Ventricular Myocytes., Biomed. Pharmacother., 186, p. 117994, DOI: 10.1016/j.biopha.2025.117994 68 10.1016/j.biopha.2025.117994 false true Reference 75862551 /api/reference/75862551 69. Zhou 1998: Properties of HERG Channels Stably Expressed in HEK 293 Cells Studied at Physiological Temperature., Biophys. J., 74, p. 230, DOI: 10.1016/S0006-3495(98)77782-3 69 10.1016/S0006-3495(98)77782-3 false true Reference 75862552 /api/reference/75862552 70. Coi 2008: Identification of “Toxicophoric” Features for Predicting Drug-Induced QT Interval Prolongation., Eur. J. Med. Chem., 43, p. 2479, DOI: 10.1016/j.ejmech.2007.12.025 70 10.1016/j.ejmech.2007.12.025 false true Reference 75862553 /api/reference/75862553 71. Cordeiro 1998: Repolarizing K+ Currents in Rabbit Heart Purkinje Cells., J. Physiol., 508, p. 811, DOI: 10.1111/j.1469-7793.1998.811bp.x 71 10.1111/j.1469-7793.1998.811bp.x false true Reference 75862554 /api/reference/75862554 72. (2026, February 05). Sotalol Dosage Guide + Max Dose, Adjustments—Drugs.Com. Available online: https://www.drugs.com/dosage/sotalol.html. 72 false true Reference 75862555 /api/reference/75862555 73. Arlin 1987: A New Regimen of Amsacrine with High-Dose Cytarabine Is Safe and Effective Therapy for Acute Leukemia., J. Clin. Oncol., 5, p. 371, DOI: 10.1200/JCO.1987.5.3.371 73 10.1200/JCO.1987.5.3.371 false true Reference 75862556 /api/reference/75862556 74. (2026, February 05). Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir Dosage Guide + Max Dose, Adjustments—Drugs.Com. Available online: https://www.drugs.com/dosage/dasabuvir-ombitasvir-paritaprevir-ritonavir.html. 74 false true Reference 75862557 /api/reference/75862557 75. (2026, February 05). Delavirdine Dosage Guide + Max Dose, Adjustments—Drugs.Com. Available online: https://www.drugs.com/dosage/delavirdine.html. 75 false true Reference 75862558 /api/reference/75862558 76. Helliwell, M.V., Zhang, Y., El Harchi, A., Dempsey, C.E., and Hancox, J.C. (2023). Inhibition of the HERG Potassium Channel by a Methanesulphonate-Free E-4031 Analogue. Pharmaceuticals, 16., DOI: 10.3390/ph16091204 76 10.3390/ph16091204 false true Reference 75862559 /api/reference/75862559 77. Carvalho 2013: Strategies To Reduce HERG K + Channel Blockade. Exploring Heteroaromaticity and Rigidity in Novel Pyridine Analogues of Dofetilide., J. Med. Chem., 56, p. 2828, DOI: 10.1021/jm301564f 77 10.1021/jm301564f false true Reference 75862560 /api/reference/75862560 78. Lu 2026: Machine Learning Models for Drug-Drug Interaction Prediction from Computational Discovery to Clinical Application., npj Digit. Med., 9, p. 198, DOI: 10.1038/s41746-026-02400-3 78 10.1038/s41746-026-02400-3 false true Reference 75862561 /api/reference/75862561 79. Liu 2024: Machine Learning and Deep Learning Approaches for Enhanced Prediction of HERG Blockade: A Comprehensive QSAR Modeling Study., Expert Opin. Drug Metab. Toxicol., 20, p. 665, DOI: 10.1080/17425255.2024.2377593 79 10.1080/17425255.2024.2377593 false true /api/publication/37325625 Kovács Zsigmond Máté et al. The Methanesulfonamide Group: Bright and Dark Sides of hERG Potassium Channel Inhibition. (2026) PHARMACEUTICALS 1424-8247 19 6<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10079012"><a href="/gui2/?type=authors&mode=browse&sel=10079012" target="_blank">Kovács Zsigmond Máté (<span class="authorship-author-name">Kovács Zsigmond Máté</span> <span class="authorAux-mtmt"> élettan</span>) </a> </span> <span class="author-affil"><span title="Debreceni Egyetem">DE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/Élettani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10084683"><a href="/gui2/?type=authors&mode=browse&sel=10084683" target="_blank">Óvári József (<span class="authorship-author-name">Óvári József</span> <span class="authorAux-mtmt"> orvostudomány</span>) </a> </span> <span class="author-affil"><span title="Debreceni Egyetem">DE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/Élettani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10001709"><a href="/gui2/?type=authors&mode=browse&sel=10001709" target="_blank">Magyar János (<span class="authorship-author-name">Magyar János</span> <span class="authorAux-mtmt"> Élettan, kórélettan</span>) </a> </span> <span class="author-affil"><span title="Debreceni Egyetem">DE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/Élettani Intézet; <span title="Debreceni Egyetem">DE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/<span title="Élettani Intézet">ElettI</span>/Sport- és Űrélettani Nem Önálló Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10001771"><a href="/gui2/?type=authors&mode=browse&sel=10001771" target="_blank">Bányász Tamás (<span class="authorship-author-name">Bányász Tamás</span> <span class="authorAux-mtmt"> Élettan, kórélettan</span>) </a> </span> <span class="author-affil"><span title="Debreceni Egyetem">DE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/Élettani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10005920"><a href="/gui2/?type=authors&mode=browse&sel=10005920" target="_blank">Nánási Péter P. (<span class="authorship-author-name">Nánási Péter Pál</span> <span class="authorAux-mtmt"> Élettan és kórélettan</span>) </a> </span> <span class="author-affil"><span title="Debreceni Egyetem">DE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/Élettani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10036941"><a href="/gui2/?type=authors&mode=browse&sel=10036941" target="_blank">Horváth Balázs (<span class="authorship-author-name">Horváth Balázs</span> <span class="authorAux-mtmt"> Élettan</span>) </a> </span> <span class="author-affil"><span title="Debreceni Egyetem">DE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/Élettani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10054274"><a href="/gui2/?type=authors&mode=browse&sel=10054274" target="_blank">Balogh Gábor (<span class="authorship-author-name">Balogh Gábor</span> <span class="authorAux-mtmt"> számítási kémia, szerkezeti biológia</span>) </a> </span> <span class="author-affil"><span title="Debreceni Egyetem">DE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/<span title="Laboratóriumi Medicina Intézet">LMI</span>/Klinikai Laboratóriumi Kutató Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10019012"><a href="/gui2/?type=authors&mode=browse&sel=10019012" target="_blank">Szentandrássy Norbert ✉ (<span class="authorship-author-name">Szentandrássy Norbert</span> <span class="authorAux-mtmt"> élettan</span>) </a> </span> <span class="author-affil"><span title="Debreceni Egyetem">DE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/Élettani Intézet</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;37325625" target="_blank">The Methanesulfonamide Group: Bright and Dark Sides of hERG Potassium Channel Inhibition</a></div> <div> <span class="journal-title">PHARMACEUTICALS</span> <span class="journal-issn">( <a target="_blank" href="https://portal.issn.org/resource/ISSN/1424-8247">1424-8247</a>)</span>: <span class="journal-volume">19</span> <span class="journal-issue">6</span> <span class="page"> Paper 882. 19 p. </span> <span class="year">(2026)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.3390/ph19060882" target="_blank" href="https://doi.org/10.3390/ph19060882"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001803776300001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001803776300001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="105042882284" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105042882284"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:black" title="42356500" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=42356500&dopt=Abstract"> PubMed </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:black" title="https://www.mdpi.com/1424-8247/19/6/882" target="_blank" href="https://www.mdpi.com/1424-8247/19/6/882"> Egyéb URL </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Drug Discovery&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Pharmaceutical Science&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Molecular Medicine&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 1</span> | Független: 0 | Függő: 1 | Nem jelölt: 0 | Scopus jelölt:&nbsp;1 | WoS/Scopus jelölt:&nbsp;1 | DOI jelölt:&nbsp;1 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;37325625&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 7 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 37325625</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Összefoglaló cikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">WoS-XML</span> </div> <div class="funder"> Adaptív és maladaptív jelátviteli mechanizmusok vizsgálata humán és emlôs szívben és agyszövetben(K 138090) Támogató: NKFIH, A TRPM4 ioncsatorna elektrofiziológiai szerepének vizsgálata emlősszíven(K 142764) Támogató: NKFIH, Mechanikai terhelés hatása a szív elektromechanikai kapcsolatára(K 147301) Támogató: NKFIH, (K139293), A direkt miozin-inhibitor aficamten elektrofiziológiai hatásai kutya kamrai szívizomsejteken(EKÖP-25-3-II-DE-105) Támogató: EKÖP </div> <div class="lastModified">Utolsó módosítás: 2026.10.13. 17:57 Szuper Admin (admin) </div> </div></div>